SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 28.08 |
| Enterprise Value ($M) | 26.79 |
| Book Value ($M) | -0.51 |
| Book Value / Share | -0.14 |
| Price / Book | -54.54 |
| NCAV ($M) | -0.52 |
| NCAV / Share | -0.14 |
| Price / NCAV | -53.74 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -16.40 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.80 |
| Current Ratio | 0.80 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1.64 |
| Assets | 1.64 |
| Liabilities | 2.16 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.16 |
| Operating Income | -13.36 |
| Net Income | -13.38 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -4.31 |
| Cash from Investing | 0.00 |
| Cash from Financing | 5.58 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Marchiando Keith | 9.40 | ||
| 13D | Payne John Bernard | 8.50 | ||
| 13D | Cornell Alison A | 7.40 | ||
| 13D/A | Maggiore Christopher D. | 14.00 | 29.06 | |
| 13D/A | Strome Mezzanine Fund, Lp | 9.10 | -53.33 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| VRPX – Virpax Pharmaceuticals, Inc. | WCUI – Wellness Center USA, Inc. |
| XSNX – NovAccess Global Inc. |
Financial data and stock pages provided by
Fintel.io